logo

PCVX

Vaxcyte·NASDAQ
--
--(--)
--
--(--)
2.07 / 10
Underperform

Evaluation yields 2.1/10, reflecting subpar financial health. Key positives: Profit-MV and Cash-MV, while concerns exist in Net profit / Total profit (%) and Revenue-MV. This configuration appears challenging.

Fundamental(2.07)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.26
Score1/3
Weight13.24%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight11.63%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-1.02%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight19.82%
1M Return7.79%
PB-ROE
Value0.41
Score0/3
Weight9.05%
1M Return3.56%
Current assets turnover ratio
Value1.78
Score2/3
Weight2.32%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.69%
1M Return0.86%
Asset-MV
Value-0.50
Score1/3
Weight24.02%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight19.84%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.59%
1M Return-0.30%
Is PCVX undervalued or overvalued?
  • PCVX scores 2.07/10 on fundamentals and holds a Premium valuation at present. Backed by its -16.78% ROE, 0.00% net margin, -12.27 P/E ratio, 2.79 P/B ratio, and -5.43% earnings growth, these metrics solidify its Underperform investment rating.